SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR ANALYZING DRUG INTERACTIONS

• US 20110082867A1
• Filed: 12/21/2009
• Published: 04/07/2011
• Est. Priority Date: 10/06/2009
• Status: Abandoned Application

• Current Assignee: NEX Step Incorporated
• Original Assignee: NEX Step Incorporated
• Inventors: Homewood, Michael A., Bruns, William A., Hostetter, Kristen L., Schulte, Sam M., Cooper, Daniel A., Montz, Robert V.
• Application Number:
  US12/643,806
• Publication Number:
  US 20110082867A1
• Time in Patent Office: Days
• US Class Current: 707/748
• CPC Class Codes: G16B 20/00 ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• CPC Class Codes: G16B 20/20 Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• CPC Class Codes: G16B 45/00 ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks

Abstract

A method, system, and computer program product. A method includes receiving a patient profile, the patient profile including a patient substance profile identifying a plurality of substances consumed by a patient and at least one patient-specific gene variant. The method includes identifying a gene associated with a first one of the plurality of substances, and performing a weighing process to determine an interaction between the first substance and the gene. The method includes producing a summary by the data processing system according to the determined interaction. Another method includes identifying at least one additional substance that has a potential effect on the patient, presenting the at least one additional substance to a user, receiving and storing a change to the patient profile based on the at least one additional substance.

Claims

1. A method for developing a patient profile in a data processing system, comprising:

receiving a patient profile in a data processing system, the patient profile including a patient substance profile identifying at least one initial substance consumed by a patient;

identifying at least one additional substance by the data processing system, based on the patient profile, that has a potential effect on the patient;

presenting the at least one additional substance to a user; and

receiving and storing a change to the patient profile in the data processing system based on the at least one additional substance.

2. The method of claim 1, wherein identifying at least one additional substance includes identifying any additional substances that are inhibitors or inducers to the gene.

3. The method of claim 1, wherein identifying at least one additional substance includes indentifying an additional substance with a potential adverse effect associated with the initial substance and a patient demographic.

4. The method of claim 1, wherein identifying at least one additional substance includes indentifying an additional substance with a potential adverse effect associated with the initial substance and a patient medical condition.

5. The method of claim 1, wherein identifying at least one additional substance includes indentifying an additional substance that has a known contraindication associated with the initial substance.

6. A method for developing a patient profile in a data processing system, comprising:

receiving a patient profile in a data processing system, the patient profile including a patient substance profile identifying a plurality of substances consumed by a patient and at least one patient-specific gene variant;

identifying, by the data processing system, a gene associated with a first one of the plurality of substances;

performing a weighing process by the data processing system according to the first substance to determine an interaction between the first substance and the gene; and

producing a summary by the data processing system according to the determined interaction.

7. The method of claim 6, wherein performing the weighing process includes determining a summation value corresponding to the patient-specific gene variant and a drug interaction value between the gene and the substance.

8. The method of claim 6, wherein performing the weighing process includes determining a summation value corresponding to the patient-specific gene variant and a sum of drug interaction values between the gene and the plurality of substances.

9. The method of claim 6, wherein the summary includes a graphical representation of each of the plurality of substances, a gene with which each substance interacts, and the type of interaction between each substance and a corresponding gene.

10. The method of claim 6, wherein the summary includes a description of patient dosing considerations according to the first substance and the determined interaction.

11. The method of claim 6, wherein the summary includes a description of a possible course of action according to the first substance and the determined interaction.

12. A data processing system comprising a processor and accessible memory, the data processing system particularly configured to perform the steps of:

receiving a patient profile, the patient profile including a patient substance profile identifying at least one initial substance consumed by a patient;

identifying at least one additional substance, based on the patient profile, that has a potential effect on the patient;

presenting the at least one additional substance to a user; and

receiving and storing a change to the patient profile based on the at least one additional substance.

13. The data processing system of claim 12, wherein identifying at least one additional substance includes identifying any additional substances that are inhibitors or inducers to the gene.

14. The data processing system of claim 12, wherein identifying at least one additional substance includes indentifying an additional substance with a potential adverse effect associated with the initial substance and a patient demographic.

15. The data processing system of claim 12, wherein identifying at least one additional substance includes indentifying an additional substance with a potential adverse effect associated with the initial substance and a patient medical condition.

16. The data processing system of claim 12, wherein identifying at least one additional substance includes indentifying an additional substance that has a known contraindication associated with the initial substance.

17. A data processing system comprising a processor and accessible memory, the data processing system particularly configured to perform the steps of:

receiving a patient profile, the patient profile including a patient substance profile identifying a plurality of substances consumed by a patient and at least one patient-specific gene variant;

identifying a gene associated with a first one of the plurality of substances;

performing a weighing process according to the first substance to determine an interaction between the first substance and the gene; and

producing a summary according to the determined interaction.

18. The data processing system of claim 17, wherein performing the weighing process includes determining a summation value corresponding to the patient-specific gene variant and a drug interaction value between the gene and the substance.

19. The data processing system of claim 17, wherein performing the weighing process includes determining a summation value corresponding to the patient-specific gene variant and a sum of drug interaction values between the gene and the plurality of substances.

20. The data processing system of claim 17, wherein the summary includes a graphical representation of each of the plurality of substances, a gene with which each substance interacts, and the type of interaction between each substance and a corresponding gene.

21. The data processing system of claim 17, wherein the summary includes a description of patient dosing considerations according to the first substance and the determined interaction.

22. The data processing system of claim 17, wherein the summary includes a description of a possible course of action according to the first substance and the determined interaction.

23. A machine-readable storage medium encoded with computer-executable instructions that, when executed, cause one or more data processing systems to collectively perform the steps of:

receiving a patient profile, the patient profile including a patient substance profile identifying at least one initial substance consumed by a patient;

identifying at least one additional substance, based on the patient profile, that has a potential effect on the patient;

presenting the at least one additional substance to a user; and

receiving and storing a change to the patient profile based on the at least one additional substance.

24. The machine-readable storage medium of claim 23, wherein identifying at least one additional substance includes identifying any additional substances that are inhibitors or inducers to the gene.

25. The machine-readable storage medium of claim 23, wherein identifying at least one additional substance includes indentifying an additional substance with a potential adverse effect associated with the initial substance and a patient demographic.

26. The machine-readable storage medium of claim 23, wherein identifying at least one additional substance includes indentifying an additional substance with a potential adverse effect associated with the initial substance and a patient medical condition.

27. The machine-readable storage medium of claim 23, wherein identifying at least one additional substance includes indentifying an additional substance that has a known contraindication associated with the initial substance.

28. A machine-readable storage medium encoded with computer-executable instructions that, when executed, cause one or more data processing systems to collectively perform the steps of:

receiving a patient profile, the patient profile including a patient substance profile identifying a plurality of substances consumed by a patient and at least one patient-specific gene variant;

identifying a gene associated with a first one of the plurality of substances;

performing a weighing process according to the first substance to determine an interaction between the first substance and the gene; and

producing a summary according to the determined interaction.

29. The machine-readable storage medium of claim 28, wherein performing the weighing process includes determining a summation value corresponding to the patient-specific gene variant and a drug interaction value between the gene and the substance.

30. The machine-readable storage medium of claim 28, wherein performing the weighing process includes determining a summation value corresponding to the patient-specific gene variant and a sum of drug interaction values between the gene and the plurality of substances.

31. The machine-readable storage medium of claim 28, wherein the summary includes a graphical representation of each of the plurality of substances, a gene with which each substance interacts, and the type of interaction between each substance and a corresponding gene.

32. The machine-readable storage medium of claim 28, wherein the summary includes a description of patient dosing considerations according to the first substance and the determined interaction.

33. The machine-readable storage medium of claim 28, wherein the summary includes a description of a possible course of action according to the first substance and the determined interaction.